CUE — Cue Biopharma, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1645460 ·
Last close
$23.18
Market Cap
$168.39M
52W High
$45.50
52W Low
$19.75
ADV30
193,488
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 5,686,000 | — | -5,363,000 | -5,178,000 | 30,877,000 | 16,379,000 | 9,269,000 |
| Dec 2025 | 21,942,000 | — | 1,958,000 | 1,585,000 | 42,212,000 | 27,136,000 | 15,780,000 |
| Sep 2025 | 2,149,000 | — | -7,544,000 | -7,448,000 | 31,644,000 | 11,701,000 | 18,398,000 |
| Jun 2025 | 2,954,000 | — | -8,635,000 | -8,482,000 | 40,707,000 | 27,492,000 | 22,548,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-24,457,000
Investing CF
$104,000
Financing CF
$27,597,000
CapEx
$-300,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-5.58
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-373,644,000
Inventory
—
Receivables
$7,250,000
ST Investments
$6,971,000
EBIT TTM
$-18,848,000
Pretax Income TTM
$-19,023,000
Interest Exp TTM
$175,000
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$37,655,000
EBITDA
$-97,284,000
Free Cash Flow
$-33,425,750
Enterprise Value
$159,863,648
Total Cash
$17,414,000
Total Debt
$3,077,000
Shares Out
7,264,414
Trailing EPS
$-29.46
Book Value
$0.44
ROE
-1603.5%
ROA
-172.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 27,466,000 | -26,521,000 | -26,602,000 | 42,212,000 | 15,780,000 | — | -21,687,000 |
| Dec 2024 | 9,287,000 | -41,593,000 | -40,674,000 | 32,191,000 | 14,692,000 | — | -36,329,000 |
| Dec 2023 | 5,490,000 | -51,992,000 | -50,733,000 | 61,530,000 | 24,445,000 | — | -39,961,000 |
| Dec 2022 | 1,245,000 | -53,502,000 | -53,010,000 | 91,283,000 | 25,601,000 | — | -41,806,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.48
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SPRB | SPRUCE BIOSCIENCES, INC. | $168.56M | $58.65 | — |
| MENS | Jyong Biotech Ltd. | $164.80M | $2.22 | — |
| LFCR | LIFECORE BIOMEDICAL, INC. \DE\ | $172.23M | $4.55 | — |
| DERM | Journey Medical Corp | $175.79M | $7.91 | — |
| OGI | ORGANIGRAM GLOBAL INC. | $177.67M | $1.26 | — |
News headlines (Yahoo Finance, 1h cache)
Cue Biopharma Announces $50.0 Million Private Placement
2026-07-10 01:40 · Yahoo
Cue Biopharma to Present at the 2026 Jefferies Global Healthcare Conference
2026-05-21 20:05 · Yahoo
Cue Biopharma Reports First Quarter 2026 Financial Results and Recent Strategic Developments
2026-05-14 20:07 · Yahoo
Cue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-05-07 23:07 · Yahoo
Cue Biopharma Announces $30 Million Private Placement
2026-04-30 20:25 · Yahoo
Cue Biopharma Expands Pipeline with Exclusive License from Ascendant Health Sciences Ltd. for Clinical-Stage Dual-Mechanism Anti-IgE Antibody
2026-04-30 20:15 · Yahoo
Cue Biopharma Names Shao-Lee Lin M.D., Ph.D., CEO, President and Board Director to Lead Continued Growth and Transformation into a Clinical-Stage Company
2026-04-30 20:05 · Yahoo
Cue Biopharma Announces 1-for-30 Reverse Stock Split
2026-04-22 12:37 · Yahoo
Cue Biopharma (CUE) Appoints Lucinda Warren as Interim President and CEO
2026-04-20 14:15 · Yahoo
Cue Biopharma to Present New Preclinical Data on Lead Autoimmune and Inflammatory Disease Candidate CUE-401 at IMMUNOLOGY2026
2026-04-15 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.